Summary of Clinical Use

A Phase 1 clinical study in patients with wet age-related macular degeneration (AMD) or diabetic macular edema (DME) is recruiting participants (June 2015). Two Phase 1 studies (as a single agent or in combination with aflibercept) in patients with solid tumours have been completed.

Mechanism Of Action and Pharmacodynamic Effects

Anti-ANGPT2 therapeutics target the angiopoietin/Tie ligand/receptor system, which is involved in blood vessel remodeling and maturation [2]. Such agents target blood vessel formation at a later stage than anti-VEGF agents, so it is foreseeable that anti-VEGF and anti-ANGPT2 agents could be combined to provide more effective anti-neovascularisation effects in tumours and other conditions where pathological vascularisation is present.